Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.36 | N/A | +5.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.36 | N/A | +5.57% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized their commitment to growth and innovation.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts to enhance product offerings and market reach.
Zoetis reported a positive surprise in EPS, which likely contributed to the stock's 1.1% increase following the earnings announcement. The lack of revenue data leaves some uncertainty, but the positive EPS performance suggests the company is managing costs effectively. Investors may view the results as a sign of resilience in a competitive market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HARTFORD INS GROUP I
Apr 29, 2013